Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy

Clinical Infectious Diseases

Volumn 28, Issue 2, 1999, Pages 331-440

  Rotstein, Coleman ^a,b,c   Bow, Eric J ^a,b,c   Laverdiere, Michel ^a,b,c   Ioannou, Stratis ^a,b,c   Carr, Danielle ^a,b,c   Moghaddam, Narguess ^a,b,c  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; FLUCONAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MYCOSIS; MYELOID LEUKEMIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0033014809     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515128     Document Type: Article

References (34)

1. 1. Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 1991;13:592-9.
2. 2. Rossetti F, Brawner DL, Bowden R, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995;20:801-11.
3. 3. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
4. 4. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized, placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
5. 5. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984;53:411-9.
6. 6. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-6.
7. 7. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
8. 8. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
9. 9. Degregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543-8.
10. 10. Flynn PM, Shenep JL, Crawford R, Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis 1995;20:964-70.
11. 11. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:688-72.
12. 12. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1993;326:845-51.
13. 13. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994;40:136-43.
14. 14. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171: 1545-52.
15. 15. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-41.
16. 16. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med 1995;71:284-6.
17. 17. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Hamatol Bluttransfus 1990;33:546-50.
18. 18. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J Antimicrob Chemother 1991;27:369-76.
19. 19. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-8.
20. 20. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-84.
21. 21. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-8.
22. 22. Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with hematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
23. 23. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106.
24. 24. Egger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. Support Care Cancer 1995;3:139-46.
25. 25. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
26. 26. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
27. 27. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-61.
28. 28. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
29. 29. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
30. 30. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society Series B 1972;34:187-200.
31. 31. Palmblad J, Lonnqvist B, Carlsson B, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukemia in adults: more bacteremias. J Intern Med 1992;231:363-70.
32. 32. Estey E, Maksymiuk A, Smith T, et al. Infection prophylaxis in acute leukemia: comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 1984;144:1562-8.
33. 33. Rotstein C, Mandell L, Goldberg N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Current Oncology 1997;4(suppl 2):S2-7.
34. 34. Kauffman CA, Liepman MK, Bergman AG, Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients: reduction of infections and effect on bacterial and fungal flora. Am J Med 1983;74:599-607.